New brain biomarker identifies pain sensitivity and may predict chronic pain risk

A novel biomarker signature combining PAF and CME predicts chronic pain risk, linking brain activity to individual pain sensitivity and treatment strategies.

NVDX-3 by Novadip Biosciences for Degenerative Spondylolisthesis: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 21, 2023

Medacta NextAR Rod Optimizer, a Disruptive Technology Redefining Rod Management in Spine Surgery, wins the 2024 Spine Technology Award from Orthopedics This Week – Biotech Investments

Medacta Group SA / Key word(s): Miscellaneous Medacta NextAR Rod Optimizer, a Disruptive Technology Redefining Rod Management in Spine Surgery, wins the 2024 Spine Technology

September 25, 2024

CNS biotech Myrobalan Therapeutics raises $24M Series A to enter the clinic

Myrobalan Therapeutics has raised $24 million to enter the clinic with one of its four CNS therapeutic candidates, with the goal of either repairing or

January 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.